Listen to this article

Cosette Pharmaceuticals Inc. completed the acquisition of Ambien and Ambien CR in the United States from Sanofi US, the Bridgewater-based company announced July 10. 

A Sanofi spokesperson told NJBIZ that financial terms of the deal are not being disclosed. Quoting data from life sciences analytic firm IQVIA, Cosette said U.S. annual sales for the prescription sleep aids for the 12 months ended April 2024 were $39 million. 

Ambien is prescribed for the short-term treatment of adults struggling with insomnia. Ambien CR is used for the treatment of adults who have trouble falling asleep and/or waking up often during the night, according to Sanofi.

“We are excited at the addition of Ambien to our portfolio,” Cosette President and CEO Apurva Saraf said in a statement. “We continue to leverage our demonstrated, best-in-class capabilities in executing complex carve-outs and integrating diverse products.” 

The Sanofi spokesperson added, “Sanofi has divested AMBIEN and AMBIEN CR to Cosette Pharmaceuticals, Inc. in the United States. To ensure uninterrupted access to patients, we will work closely with Cosette Pharmaceuticals, Inc., and remain connected to the products during the post-closing transition period. The decision to divest AMBIEN aligns with Sanofi’s ongoing transformation to deliver first-in-class and best-in-class medicines while continuing to operate with excellence for our customers and patients.”

Cosette’s pharmaceutical portfolio includes products in women’s health, cardiology and dermatology, such as topical creams, ointments, oral liquids/solutions and suppositories. The company has corporate and manufacturing facilities in the Garden State and North Carolina. It employs more than 300 workers. 

Some of Cosette’s latest acquisitions include women’s health treatments Vyleesi from Palatin Technologies Inc. in January and Intrarosa from Endoceutics Inc. in June 2023. Financial terms of those deals also were not disclosed.